Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax for leukocytosis during induction in acute promyelocytic leukemia
ChiCTR2600122074Phase 4Recruiting
- Sponsor
- Linyi People's Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of venetoclax in Acute promyelocytic leukaemia (APL) (2 arms), sponsored by Linyi People's Hospital. Primary endpoint: Rate of WBC decline and peak control. Started Apr 2026; status: recruiting.
02
Drugs
venetoclax
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on ChiCTR2600122074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122074.